8-K: Aardvark Therapeutics Q3 2025: PWS Trial Expanded, Obesity Drug Advances

Aardvark Therapeutics reported Q3 2025 financial results, expanded its PWS Phase 3 trial, and advanced its obesity drug candidate ARD-201 with promising preclinical data.

Summary

• Reported financial results for the third quarter ended September 30, 2025, and provided pipeline and business updates.
• Aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for Prader-Willi Syndrome (PWS).
• Presented new preclinical data at ObesityWeek 2025 demonstrating the potential of ARD-201 in enhanced glucose control and preservation of lean body mass.
• Oral ARD-201 shows potential for weight management after GLP-1RA discontinuation, supported by new promising preclinical results and ARD-101 clinical data.
• Held $126.4 million in cash, cash equivalents, and short-term investments as of September 30, 2025, which supports projected operations into 2027.
• Net loss for the quarter ended September 30, 2025, was $16.3 million, compared to $4.2 million for the same period in 2024.
• Research and development expenses increased to $13.7 million for Q3 2025 from $4.1 million for Q3 2024.
• General and administrative expenses increased to $4.0 million for Q3 2025 from $1.0 million for Q3 2024.

Sentiment

Score: 6

Explanation: The financial results show a significant increase in net loss and expenses, which is negative. However, the clinical and preclinical pipeline updates, particularly the FDA alignment for ARD-101 and promising data for ARD-201 addressing key industry challenges, are positive developments that balance the financial burn. The cash runway into 2027 provides stability despite the losses.

Positives

• FDA alignment to lower the minimum age of eligibility for the HERO Phase 3 trial (ARD-101 for PWS) from 13 to 10 years, broadening the eligible patient population and expanding the potential target market.
• Commenced enrollment for the HERO Open Label Extension (OLE) trial and initiated first clinical trial sites in Australia.
• New preclinical data for ARD-201 demonstrates potential for enhanced glucose control and preservation of lean body mass, addressing key challenges in obesity treatment.
• Preclinical and clinical data support ARD-201's potential to attenuate weight gain, promote weight loss, and help maintain weight after GLP-1RA discontinuation.
• ARD-101 showed signals of weight control, reduced hunger, and improved metabolic parameters in a Phase 2A study in adults with obesity, with good tolerability and no serious adverse events.
• Cash, cash equivalents, and short-term investments of $126.4 million provide a projected cash runway into 2027.

Negatives

• Net loss for the quarter ended September 30, 2025, was $16.3 million, a significant increase from $4.2 million for the same period in 2024.
• Research and development expenses increased by $9.7 million to $13.7 million for Q3 2025 compared to Q3 2024, primarily due to increased development costs for ARD-101 and personnel-related expenses.
• General and administrative expenses increased by $2.9 million to $4.0 million for Q3 2025 compared to Q3 2024, primarily due to increases in personnel-related costs, facilities, and professional fees related to commencing operations as a public company.

Risks

• Uncertainties related to potential delays in the commencement, enrollment, and completion of clinical trials.
• Risk that capital resources may be used sooner than expected and may be insufficient to achieve anticipated milestones.
• Dependence on third parties for manufacturing, shipping, and production of drug product for use in clinical and preclinical trials.
• Risk of unfavorable clinical trial results.
• Risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results.

Future Outlook

The company expects topline data from the Phase 3 HERO trial evaluating ARD-101 for PWS in the third quarter of 2026. Preliminary or interim data from the Phase 2 POWER trial is anticipated in the second half of 2026. Existing cash, cash equivalents, and short-term investments are projected to fund operations into 2027.

Management Comments

• "During ObesityWeek, we highlighted new preclinical data demonstrating the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today's obesity treatment landscape. The data were met with encouraging feedback from Key Opinion Leaders who attended the meeting."
• "We also presented clinical data on ARD-101 and preclinical data on ARD-201 demonstrating the potential of oral ARD-201 to attenuate weight gain, promote weight loss and help maintain weight after GLP-1RA discontinuation."
• "We're looking forward to advancing ARD-201 into two Phase 2 trials, POWER and STRENGTH, to further evaluate its potential for individuals living with metabolic obesity."

Industry Context

Aardvark Therapeutics is developing novel small-molecule therapeutics that target innate homeostatic pathways to suppress hunger, a distinct mechanism from appetite. Their ARD-201 program aims to address significant unmet needs in the competitive obesity treatment landscape, particularly by offering enhanced glucose control, preserving lean body mass, and managing weight after the discontinuation of GLP-1RA therapies, which are currently dominant but have limitations.

Comparison to Industry Standards

• ARD-201's preclinical data showed glucose control comparable to high-dose tirzepatide (a dual GLP-1RA/GIP receptor agonist) and further enhanced glucose clearance when combined with low-dose tirzepatide.
• ARD-201 demonstrated preservation of lean body mass, which is a key differentiator and potential advantage over some existing anti-obesity therapies that can lead to significant lean mass loss.
• ARD-101's tolerability profile, with no serious adverse events or treatment discontinuations in its Phase 2A study, suggests a distinct and potentially favorable safety profile compared to effects associated with some current anti-obesity therapies.

Stakeholder Impact

• Shareholders: Increased R&D and G&A expenses lead to a higher net loss, but positive clinical progress and a solid cash runway into 2027 could support future valuation.
• Patients (PWS): Expanded eligibility for the HERO trial (age 10+) offers more children access to a potential treatment for hyperphagia.
• Patients (Obesity): Potential for ARD-201 to offer improved glucose control and lean body mass preservation, and address weight regain after GLP-1RA discontinuation, could provide new treatment options.
• Employees: Continued clinical development and operations suggest stable employment, with increased personnel-related costs noted.

Next Steps

• Advance ARD-201 into two Phase 2 trials, POWER and STRENGTH, to further evaluate its potential for individuals living with metabolic obesity.
• Continue enrollment for the HERO Open Label Extension (OLE) trial.
• Await topline data from the Phase 3 HERO trial evaluating ARD-101 for PWS in Q3 2026.
• Await preliminary or interim data from the Phase 2 POWER trial in 2H 2026.

Key Dates

Recommendation

While the increased net loss and expenses are concerning, they are largely driven by accelerated clinical development, which is a necessary investment for a biopharmaceutical company. The positive clinical updates, including FDA alignment for ARD-101 and promising preclinical data for ARD-201, represent significant progress in addressing unmet medical needs in large markets (PWS and obesity). The projected cash runway into 2027 provides sufficient time to reach key clinical milestones. Investors should hold to monitor the upcoming Phase 3 and Phase 2 data readouts, which will be critical determinants of future value.

Keywords

Aardvark Therapeutics, ARD-101, ARD-201, Prader-Willi Syndrome, PWS, hyperphagia, obesity, metabolic diseases, GLP-1RA, clinical trials, Phase 3, Phase 2, biopharmaceutical, drug development, glucose control, lean body mass, weight management, Q3 2025 financial results